Core Insights - The company, 泰德医药 (03880), reported a revenue of 254 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 28.52% [1] - Shareholder profit attributable to the company was 102 million RMB, which is a significant year-on-year increase of 101.71% [1] - Basic earnings per share were reported at 0.82 RMB [1] - The increase in revenue is primarily attributed to the growth in FFS and FTE business segments, driven by increased demand for the company's services [1]